Evidence map›Paper›PMID 35619666›Full record

ArticleInternational journal of physiology, pathophysiology and pharmacology2022

Estimated change of COVID-19 vaccine efficacy due to omicron variant SARS CoV2.

Rujittika Mungmunpuntipantip, Viroj Wiwanitkit

Abstract read
In one paragraph

Article in International journal of physiology, pathophysiology and pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rujittika MungmunpuntipantipPrivate Academic Consultant Bangkok, Thailand.
Viroj WiwanitkitHonorary Professor, Dr DY Patil University Pune, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19, an infection caused by SARS CoV2, is a worldwide public health problem at present. Pandemic of this respiratory viral infection has occurred since 2020. Recently, in late 2021, the new variant of SARS CoV2, omicron, was reported from Africa and already cause problems in many countries. Regarding omicron variant, there are many mutations within the molecule of SARS CoV2. The effect of molecular change is unknown and the study on its clinical impact is interesting. An important possible clinical impact of the mutation in omicron is a change of COVID-19 vaccine efficacy. Herein, we used a clinical mathematical model to assess the effect of mutations in omicron variants on vaccine efficacy. Compared to classical SARS CoV2, the omicron form has a large estimated decrease, believed to be roughly 12 times normal. Therefore, it is necessary to find out a new effective vaccine for controlling of the new omicron variant.

Indexed as

COVID-19efficacyOmicronvaccinevariant

Identifiers

PMID35619666
PMCPMC9123475

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.